fibrolamellar
carcinoma
flc
rare
therapeut
intract
liver
cancer
disproportion
affect
youth
although
flc
tumor
exhibit
distinct
gene
express
profil
caus
transcript
mechan
remain
unclear
use
chromatin
runon
sequenc
discov
approxim
enhanc
enhanc
hotspot
activ
flc
rel
nonmalign
liver
detail
bioinformat
analys
reveal
aberr
erkmek
signal
candid
master
transcript
regul
also
defin
gene
strongli
associ
aberr
flc
enhanc
activ
includ
treatment
flc
cell
model
inhibitor
independ
reduc
cell
viabil
andor
significantli
enhanc
effect
mek
inhibitor
cobimetinib
find
highlight
new
molecular
target
drug
develop
well
novel
drug
combin
approach
fibrolamellar
carcinoma
flc
rare
type
liver
cancer
predominantli
affect
adolesc
young
adult
prior
histori
liver
diseas
craig
et
al
torbenson
current
surgic
resect
effect
treatment
flc
howev
patient
metastat
diseas
time
diagnosi
make
surgic
cure
difficult
stipa
et
al
patient
success
treat
chemotherapi
molecular
therapi
standard
treatment
regimen
flc
patient
torbenson
furthermor
flc
often
drug
resist
frequent
recur
follow
initi
treatment
maniaci
et
al
underscor
need
develop
effect
therapi
cancer
flc
genet
character
kb
heterozyg
delet
chromosom
lead
format
fusion
honeyman
et
al
fusion
occur
least
patient
cornella
et
al
honeyman
et
al
specif
flc
dinh
et
al
graham
et
al
kastenhub
et
al
suffici
drive
liver
tumor
format
mice
engelholm
et
al
kastenhub
et
al
multipl
group
perform
genomescal
analys
identifi
dysregul
gene
cornella
et
al
dinh
et
al
griffith
et
al
malouf
et
al
simon
et
al
sorenson
et
al
xu
et
al
long
noncod
rna
dinh
et
al
microrna
dinh
et
al
farber
et
al
flc
yet
littl
known
caus
transcript
regulatori
mechan
lead
aberr
gene
express
flc
tumor
format
precis
spatial
tempor
regul
gene
express
essenti
mani
biolog
process
one
class
cisregulatori
element
play
major
role
transcript
regul
gene
express
enhanc
enhanc
classic
defin
stretch
noncod
dna
promot
transcript
target
gene
irrespect
genom
context
orient
substanti
extent
distanc
well
blackwood
kadonaga
enhanc
often
celltyp
specif
allow
precis
spatiotempor
control
gene
transcript
differ
cell
type
within
organ
heintzman
et
al
nord
et
al
recent
work
suggest
least
ten
thousand
activ
enhanc
given
cell
type
dunham
et
al
activ
enhanc
serv
bind
site
transcript
factor
transcript
coactiv
rna
polymeras
thought
interact
cognat
promot
threedimension
loop
explain
abil
act
long
distanc
long
et
al
recent
studi
shown
activ
enhanc
transcrib
produc
enhanc
rna
erna
kim
et
al
de
santa
et
al
genomewid
identif
enhanc
detect
erna
recent
becom
possibl
coupl
nascent
transcript
runon
assay
high
throughput
sequenc
eg
global
runon
groseq
precis
runon
sequenc
proseq
groseq
core
et
al
proseq
kwak
et
al
requir
isol
cellular
nuclei
make
applic
method
primari
tissu
extraordinarili
difficult
overcom
limit
chromatin
runon
sequenc
chroseq
develop
extend
techniqu
permit
analysi
primari
fresh
frozen
tissu
chu
et
al
addit
advent
sister
techniqu
call
length
extens
chroseq
lechroseq
permit
investig
sampl
degrad
rna
chu
et
al
technic
advanc
final
enabl
studi
nascent
transcript
enhanc
promot
gene
loci
fresh
archiv
primari
human
tumor
tissu
chroseq
recent
success
use
identifi
distinct
transcript
program
differ
subtyp
glioblastoma
multiform
chu
et
al
perform
chroseq
primari
flc
match
nonmalign
liver
nml
sampl
flc
rare
adolesc
cancer
order
identifi
tre
activ
transcrib
flc
rel
nml
quantifi
chroseq
read
within
tre
across
sampl
use
algorithm
love
et
al
perform
differenti
transcript
analysi
fig
approach
led
identif
tre
significantli
activ
transcrib
flc
fig
c
fdr
fold
chang
refer
flcspecif
tre
also
identifi
nmlspecif
tre
flcand
nmlspecif
tre
locat
intron
intergen
tss
region
show
major
differ
tre
length
fig
b
transcript
factor
motif
enrich
analysi
conditionspecif
tre
use
homer
heinz
et
al
reveal
signific
enrich
flcspecif
tre
motif
creb
fig
activ
mapk
signal
similar
analysi
nmlspecif
tre
show
enrich
motif
tabl
addit
analysi
promot
gene
nearest
flcspecif
tre
use
genom
region
enrich
annot
tool
great
mclean
et
al
reveal
signific
enrich
motif
creb
famili
member
well
jun
fig
separ
examin
flcspecif
promot
proxim
tre
enhanc
distal
tre
reveal
promot
enrich
myb
fig
tabl
enhanc
enrich
creb
fig
found
flcspecif
enhanc
contain
motif
contain
creb
motif
flc
copyright
holder
preprint
peerreview
http
specif
tre
contain
creb
motif
enrich
motif
tabl
result
suggest
flc
character
aberr
map
regulatori
element
strongli
associ
transcript
factor
creb
famili
myb
famili
order
determin
gene
regul
flcspecif
tre
first
defin
genom
window
around
tss
promoterenhanc
interact
occur
within
hundr
kilobas
javierr
et
al
defin
kb
window
upstream
downstream
gene
tss
next
quantifi
number
flcspecif
enhanc
within
window
fig
anticip
observ
gene
flcspecif
enhanc
window
highli
transcrib
flc
nml
compar
gene
fewer
flcspecif
enhanc
window
fig
howev
import
note
enhanc
within
gene
window
like
regul
gene
address
point
quantit
later
manuscript
next
rank
gene
activ
transcrib
flc
chroseq
tpm
accord
number
flcspecif
enhanc
window
top
rank
gene
analysi
fig
tabl
also
observ
two
gene
overexpress
flc
dinh
et
al
high
densiti
flcspecif
enhanc
sinc
discov
motif
creb
enrich
flcspecif
tre
fig
next
focus
target
gene
transcript
factor
flc
specif
rank
gene
densiti
flcspecif
enhanc
contain
one
creb
motif
basi
criteria
highest
densiti
flcspecif
enhanc
contain
motif
fig
also
highli
rank
version
analysi
highest
second
highest
densiti
flcspecif
enhanc
contain
creb
motif
respect
fig
next
found
gene
least
one
nearbi
flcspecif
enhanc
contain
either
creb
motif
overrepres
mapk
signal
pathway
kegg
fisher
exact
test
significantli
enrich
target
interact
protein
ppi
hub
protein
fisher
exact
test
rank
gene
accord
densiti
flcspecif
enhanc
contain
creb
motif
tabl
show
result
transcript
factor
motif
enrich
flcspecif
tre
compar
nonflcspecif
tre
flcspecif
promot
compar
nonflcspecif
promot
f
flcspecif
enhanc
compar
nonflcspecif
enhanc
g
full
result
shown
tabl
e
great
analysi
predict
promot
motif
gene
associ
flcspecif
tre
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
fig
observ
gene
least
one
nearbi
flcspecif
enhanc
contain
creb
motif
enrich
target
interact
protein
fig
taken
togeth
result
suggest
regul
gene
flcspecif
enhanc
may
mediat
creb
transcript
factor
may
contribut
andor
result
dysregul
mapk
signal
gene
window
analys
fig
identifi
gene
may
regul
flcspecif
enhanc
howev
nearbi
gene
may
tre
within
window
order
confid
link
individu
flcspecif
enhanc
put
gene
target
correl
enhanc
activ
gene
transcript
level
across
flc
tumor
describ
previous
corc
et
al
chroseq
allow
us
quantifi
enhanc
activ
gene
transcript
singl
experiment
dataset
therebi
avoid
confound
variabl
aris
use
multipl
differ
assay
correl
transcript
activ
enhanc
gene
within
kb
compar
null
distribut
interchromosom
enhancergen
pair
calcul
pvalu
fig
b
window
larger
smaller
kb
reduc
power
detect
statist
signific
geneenhanc
correl
fig
use
fdr
link
flcspecif
enhanc
put
target
gene
fig
c
expect
observ
frequenc
predict
geneenhanc
link
decreas
increas
distanc
fig
found
enhanc
link
one
two
gene
mean
fig
gene
link
one
two
enhanc
mean
fig
top
gene
term
enhanc
connect
link
least
enhanc
fig
tabl
top
includ
vcan
fig
fig
put
link
fig
tabl
interestingli
highli
transcrib
nml
substanti
amount
chroseq
signal
promot
fig
indic
polymeras
paus
unlik
observ
locu
fig
chroseq
signal
nml
even
tss
observ
suggest
transcript
paus
may
anoth
mechan
regul
express
therefor
may
pois
express
wherea
locu
complet
inact
nml
dramat
rewir
activ
flc
super
enhanc
noncod
region
exhibit
unusu
high
transcript
activ
et
al
pott
lieb
whyte
et
al
import
regul
cell
ident
whyte
et
al
key
cancer
gene
et
al
use
algorithm
analog
one
previous
use
defin
super
enhanc
chromatin
immunoprecipit
sequenc
chipseq
data
et
al
whyte
et
al
identifi
cluster
enhanc
remark
high
transcript
activ
flc
nml
fig
see
materi
method
use
flcspecif
enhanc
input
identifi
dens
cluster
especi
high
flcspecif
transcript
activ
fig
loci
consist
flcspecif
enhanc
instead
enhanc
present
flc
refer
flcspecif
enhanc
hotspot
rather
flc
super
enhanc
super
enhanc
shown
regul
key
cancer
driver
et
al
link
flcspecif
enhanc
hotspot
closest
gene
robustli
transcrib
chroseq
tpm
significantli
increas
transcript
chroseq
fdr
chang
flc
compar
nml
sever
gene
consist
link
flc
includ
oat
other
previous
report
dysregul
flc
repres
novel
candid
oncogen
enrich
analysi
gene
link
flcspecif
enhanc
hotspot
reveal
signific
overrepresent
comput
predict
geneenhanc
link
flcspecif
tre
creb
motif
within
flcspecif
tre
blue
motif
within
flcspecif
tre
green
shown
gene
diagram
flcspecif
tre
contain
creb
motif
shown
blue
contain
motif
green
contain
creb
motif
purpl
other
black
transcript
signal
plu
minu
strand
shown
red
grey
respect
flc
nml
show
similar
level
paus
polymeras
peak
tss
flc
significantli
gene
bodi
transcript
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mapk
signal
pathway
fig
enrich
target
fig
correl
analysi
use
databas
lachmann
et
al
demonstr
gene
also
strongli
link
jun
express
fig
find
consist
previou
analysi
jun
may
critic
transcript
regul
gene
determin
uniqu
flcspecif
enhanc
hotspot
compar
previous
identifi
super
enhanc
sedb
jiang
et
al
databas
contain
super
enhanc
human
sampl
across
cell
tissu
type
includ
normal
human
liver
primari
hepatocyt
multipl
cell
line
includ
found
flcspecif
enhanc
hotspot
present
sampl
sedb
notabl
includ
link
fig
g
tabl
indic
mechan
transcript
regul
gene
may
uniqu
flc
flcspecif
enhanc
hotspot
associ
show
minim
intersect
super
enhanc
sedb
fig
overlap
super
enhanc
respect
addit
flcspecif
enhanc
hotspot
includ
associ
overlap
super
enhanc
liverderiv
sampl
includ
healthi
liver
hepatocellular
carcinoma
cell
line
investig
uniqu
flcspecif
enhanc
hotspot
present
sedb
crossreferenc
enhanc
hotspot
individu
enhanc
identifi
encod
nih
roadmap
epigenom
consortia
see
materi
method
one
flcspecif
enhanc
hotspot
locat
near
overlap
individu
enhanc
record
three
databas
mention
suggest
enhanc
hotspot
truli
uniqu
flc
fig
also
recalcul
signal
flcspecif
super
enhanc
includ
individu
enhanc
overlap
enhanc
three
databas
revis
stitch
enhanc
close
exhibit
enough
transcript
activ
chroseq
signal
still
meet
threshold
set
origin
analysi
enhanc
hotspot
result
suggest
substanti
amount
enhanc
activ
potenti
complet
uniqu
flc
loci
gene
significantli
correl
flcspecif
enhanc
significantli
associ
flcspecif
enhanc
hotspot
repres
gene
like
drive
key
oncogen
attribut
flc
cell
refin
list
identifi
highconfid
candid
integr
chroseq
result
rnaseq
data
flc
sampl
tabl
ten
also
underw
chroseq
analysi
first
select
gene
identifi
significantli
correl
flcspecif
enhanc
fig
link
flcspecif
enhanc
hotspot
fig
gene
filter
identifi
gene
highli
transcrib
chroseq
tpm
fold
chang
fdr
express
rnaseq
normal
count
fold
chang
fdr
flc
rel
nml
integr
chroseq
rnaseq
data
ensur
transcript
chang
gene
maintain
steadi
state
rna
level
final
list
harbor
gene
fig
tabl
notic
half
gene
previous
implic
drug
resist
tesc
vcan
connect
elev
mapkerk
activ
tesc
vcan
tabl
select
eight
gene
oat
tesc
vcan
investig
chose
high
densiti
flcspecif
enhanc
fig
creb
motif
fig
respect
greatest
number
significantli
correl
enhanc
fig
tesc
vcan
previous
strongli
implic
drug
resist
li
et
al
man
et
al
salient
featur
flc
maniaci
et
al
torbenson
oat
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
previous
identifi
candid
marker
flc
dinh
et
al
promin
mediat
drug
resist
cancer
type
boyd
et
al
doyen
et
al
kopecka
et
al
yoo
et
al
encod
member
heat
shock
protein
famili
shown
interact
fusion
found
flc
also
select
one
gene
appear
flcspecif
enhanc
hotspot
analysi
anoth
geneenhanc
correl
analysi
investig
fig
compar
express
gene
flc
cancer
type
within
cancer
genom
atla
tcga
found
highli
express
flc
cancer
type
fig
tesc
vcan
also
highli
express
flc
addit
sever
cancer
type
within
tcga
fig
also
compar
express
flc
compar
normal
tissu
within
genotypetissu
express
gtex
databas
found
substanti
higher
level
flc
normal
tissu
fig
vcan
respons
gene
select
overtranscrib
fig
overexpress
fig
flc
rel
nml
unclear
whether
dysregul
directli
caus
fusion
determin
whether
fusion
suffici
perturb
gene
interest
took
advantag
two
murin
model
flc
first
model
transposon
express
human
introduc
liver
mice
hydrodynam
tail
vein
inject
form
flclike
liver
tumor
kastenhub
et
al
examin
express
gene
interest
result
liver
tumor
compar
liver
mice
inject
empti
vector
control
mous
homolog
human
display
significantli
higher
express
sampl
express
compar
control
fig
second
model
cell
line
undergon
gene
edit
result
heterozyg
delet
analog
endogen
event
human
lead
format
fusion
dinh
et
al
turnham
et
al
examin
express
gene
interest
cell
express
found
well
vcan
significantli
elev
compar
wildtyp
wt
control
fig
primatespecif
lncrna
reitmair
et
al
use
altern
nonmurin
model
studi
regul
specif
stabli
overexpress
fusion
human
hepatoma
cell
line
use
lentivir
system
express
dramat
increas
express
compar
enhanc
green
fluoresc
protein
egfp
control
fig
wt
prkaca
also
increas
express
howev
magnitud
induct
significantli
larger
fusion
compar
wt
prkaca
indic
someth
canon
pka
activ
possibl
domain
relev
robust
induct
importantli
stabl
express
kinasedead
mutant
increas
express
fig
indic
kinas
activ
fusion
necessari
induct
express
determin
might
respons
pka
fusion
context
examin
cholangiocarcinoma
dataset
nakamura
et
al
character
tumor
fusion
involv
prkaca
prkacb
atpas
nak
transport
subunit
beta
interestingli
exon
prkaca
retain
fusion
use
rnaseq
data
gener
dataset
examin
relationship
pka
fusion
express
tumor
pka
fusion
demonstr
significantli
higher
express
tumor
without
pka
fusion
fig
indic
respons
pka
activ
altern
fusion
event
result
suggest
suffici
perturb
express
vcan
specif
diseas
model
use
regul
depend
upon
least
kinas
activ
top
gene
associ
flcspecif
enhanc
hotspot
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
result
thu
far
suggest
mapk
signal
regul
flc
pathogenesi
fig
confirm
mapk
signal
overact
flc
measur
level
phosphoryl
mek
erk
wt
cell
fig
b
expect
observ
dramat
increas
phosphomek
phosphoerk
cell
express
fusion
compar
wt
cell
treatment
cell
express
mek
inhibitor
cobimetinib
result
doserespons
decreas
cell
viabil
fig
identifi
promin
flcenhancerhotspot
associ
gene
implic
drug
resist
cancer
doyen
et
al
januchowski
et
al
kopecka
et
al
report
previous
mediat
effect
mapk
pathway
hsieh
et
al
knockdown
sirna
dramat
reduc
viabil
cell
express
also
increas
potenc
cobimetinib
fig
knockdown
much
effect
combin
cobimetinib
significantli
reduc
cell
viabil
compar
cobimetinib
alon
fig
f
fig
next
test
whether
inhibit
mapk
signal
reduc
viabil
human
flc
tumor
cell
first
deriv
primari
human
flc
cell
line
patientderiv
xenograft
pdx
model
optim
previous
describ
protocol
dinh
et
al
liu
et
al
see
materi
method
treatment
cobimetinib
reduc
erk
phosphoryl
expect
fig
significantli
decreas
flc
cell
viabil
fig
higher
dose
drug
effect
confirm
across
three
distinct
deriv
flc
cell
line
fig
fig
posit
express
result
suggest
flc
cell
suscept
mapk
inhibit
howev
dose
need
cytotox
effect
indic
intrins
level
drug
resist
cell
hypothes
inhibit
flc
cell
may
mitig
intrins
drug
resist
result
cell
express
fig
effect
inhibitor
current
clinic
trial
combin
therapi
metastat
pancreat
cancer
found
pharmacolog
suppress
flc
cell
significantli
enhanc
potenc
cobimetinib
nm
dose
fig
fig
effect
confirm
across
three
distinct
deriv
flc
cell
line
quantifi
interact
cobimetinib
use
combin
index
ci
cobimetinib
combin
treatment
result
synergist
respons
ci
cobimetinib
cobimetinib
ci
indic
synergi
determin
whether
interact
mapk
signal
pathway
inhibit
either
mek
cobimetinib
treatment
result
decreas
erk
phosphoryl
expect
effect
express
fig
howev
treatment
reduc
phosphoryl
mek
erk
level
fig
suggest
may
function
least
part
upstream
mapk
signal
pathway
taken
togeth
result
suggest
mapk
signal
pathway
dysregul
flc
inhibit
pathway
combin
pharmacolog
suppress
inhibit
repres
excit
candid
molecular
therapeut
approach
fibrolamellar
carcinoma
devast
cancer
affect
young
adult
limit
treatment
option
thu
remain
great
need
identifi
potenti
therapeut
target
analyz
primari
flc
tumor
match
nml
sampl
map
uniqu
enhanc
landscap
flc
one
goal
studi
discov
master
regul
dysregul
gene
express
signal
flc
took
advantag
new
techniqu
le
chroseq
chu
et
al
allow
us
perform
runon
sequenc
frozen
primari
tumor
notabl
advantag
le
chroseq
allow
quantif
enhanc
activ
gene
transcript
singl
experi
therebi
avoid
possibl
confound
associ
use
multipl
differ
assay
find
flcspecif
tre
enrich
motif
creb
noteworthi
sever
reason
first
creb
wellvalid
substrat
wildtyp
pka
shaywitz
greenberg
previous
shown
hyperphosphoryl
flc
compar
adjac
liver
xu
et
al
second
creb
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
transcript
activ
chen
et
al
chen
et
al
reitmair
et
al
repress
keller
et
al
latter
candid
tumor
suppressor
flc
dinh
et
al
third
creb
heterodim
consist
fo
jun
subunit
shown
regul
et
al
sanyal
et
al
final
creb
activ
mapk
signal
pathway
ginti
et
al
karin
wu
et
al
xing
et
al
dysregul
flc
analysi
reveal
transcript
distal
tre
ie
enhanc
stratifi
flc
nml
sampl
better
transcript
proxim
tre
gene
bodi
similar
previou
report
corc
et
al
corc
et
al
find
consist
studi
franco
et
al
van
groningen
et
al
ooi
et
al
shown
enhanc
activ
sensit
gene
express
sampl
classif
eg
tumornorm
tumor
subtyp
cell
type
unlik
method
identifi
enhanc
assay
transposaseaccess
chromatin
use
sequenc
atacseq
chromatin
immunoprecipit
sequenc
chipseq
enhancerassoci
histon
modif
protein
chroseq
identifi
activ
regulatori
element
well
activ
transcrib
gene
advantag
allow
us
correl
enhanc
gene
transcript
within
assay
well
provid
direct
output
enhanc
function
transcript
steadi
state
rna
level
reflect
cumul
effect
transcript
cotranscript
posttranscript
regulatori
process
identifi
put
target
flcspecif
enhanc
employ
comput
approach
base
enhanc
densiti
signal
correl
identifi
flcspecif
enhanc
hotspot
defin
dens
cluster
enhanc
especi
high
transcript
activ
similar
concept
super
enhanc
compar
loci
previous
character
super
enhanc
sedb
found
flcspecif
enhanc
hotspot
complet
uniqu
overlap
known
super
enhanc
furthermor
enhanc
hotspot
overlap
super
enhanc
previous
assay
liver
tissu
liverderiv
cell
super
enhanc
shown
regul
cell
ident
oncogen
et
al
find
suggest
flcspecif
enhanc
hotspot
may
regul
gene
import
format
progress
andor
mainten
cancer
super
enhanc
regul
bromodomain
protein
et
al
inhibitor
filippakopoulo
et
al
shown
disrupt
super
enhanc
function
gryder
et
al
et
al
mack
et
al
peeter
et
al
pharmacolog
disrupt
flcspecif
enhanc
hotspot
describ
may
repres
altern
therapeut
approach
flc
comput
identifi
geneenhanc
interact
studi
howev
futur
experi
import
confirm
interact
experiment
care
dissect
regulatori
interact
flc
exampl
method
base
chromosom
conform
captur
hic
identifi
confirm
global
chromosom
interact
method
base
luciferas
assay
selftranscrib
activ
regulatori
region
sequenc
starrseq
massiv
parallel
report
assay
valid
regulatori
activ
identifi
enhanc
refin
dissect
individu
subset
enhanc
use
genom
edit
confirm
function
geneenhanc
link
identifi
specif
nucleotid
within
enhanc
essenti
regul
furthermor
chroseq
experi
conduct
primari
tumor
contain
heterogen
mixtur
cell
result
therefor
repres
aggreg
result
across
cell
type
present
go
forward
singl
cell
experi
necessari
dissect
role
transcript
regulatori
network
tumor
immun
parenchym
cell
type
within
primari
tumor
integr
analys
chroseq
rnaseq
data
identifi
highconfid
candid
oncogen
flc
gene
includ
character
cancer
previous
known
overexpress
flc
dinh
et
al
cancer
chen
et
al
chen
et
al
shi
et
al
promot
chemotherapeut
resist
colon
cancer
head
neck
squamou
cell
carcinoma
han
et
al
link
drug
resist
multipl
cancer
type
boyd
et
al
doyen
et
al
kopecka
et
al
previous
demonstr
overexpress
flc
dinh
et
al
gene
includ
rel
understudi
merit
deeper
investig
har
wellcharacter
inhibitor
gene
may
repres
potenti
expedi
avenu
new
flc
therapeut
one
notabl
exampl
inhibitor
current
clinic
trial
metastat
pancreat
cancer
see
gene
identifi
current
target
drug
inhibitor
nonetheless
altern
strategi
exist
target
cell
uniqu
express
gene
drug
conjug
antibodi
aptam
bind
cell
surfac
protein
specif
cell
interest
flc
cell
repres
emerg
strategi
target
tumor
cell
examin
express
genotypetissu
express
gtex
databas
demonstr
substanti
higher
express
flc
tumor
normal
tissu
indic
may
use
molecular
beacon
approach
noncel
surfac
protein
method
modifi
engin
tcell
recogn
major
histocompat
complex
mhc
class
present
specif
peptid
protein
interest
leverag
knowledg
gain
studi
develop
new
target
therapeut
approach
remain
import
goal
analys
show
larg
proport
gene
associ
flcspecif
enhanc
function
drug
resist
includ
han
et
al
wang
et
al
vcan
li
et
al
boyd
et
al
doyen
et
al
kopecka
et
al
yoo
et
al
suggest
high
express
gene
may
respons
strong
drug
resist
phenotyp
observ
flc
thu
viabl
therapeut
strategi
combat
drug
resist
may
combin
inhibitor
drug
resist
gene
present
avail
therapeut
exampl
ongo
clinic
trial
metastat
pancreat
cancer
focus
combin
inhibitor
standard
therapeut
gemcitabin
clinicaltrialsgov
identifi
addit
demonstr
vcan
respons
least
one
two
differ
genet
engin
murin
model
flc
howev
notic
signific
induct
express
sever
flc
enhancerhotspot
associ
gene
test
even
though
overexpress
primari
flc
tumor
sever
possibl
explan
observ
first
murin
model
use
might
speciesspecif
differ
gene
regul
compar
human
second
gene
might
directli
downstream
induc
due
anoth
process
tumor
initi
progress
exampl
certain
gene
may
induc
respons
develop
tumor
fibrosi
within
flc
tumor
although
distinct
featur
primari
human
flc
current
mous
model
lack
characterist
provid
possibl
explan
observ
differ
indic
critic
need
better
model
system
result
use
two
murin
model
suggest
least
vcan
respons
altern
model
may
necessari
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
studi
remain
gene
exampl
sinc
primatespecif
lncrna
use
cell
line
stabli
express
demonstr
respons
fusion
final
demonstr
mapk
signal
pathway
dysregul
flc
cell
line
deriv
use
knowledg
publish
flc
cell
line
without
limit
flc
cell
deriv
pdx
model
cocultur
irradi
mous
fibroblast
observ
murin
compon
deriv
cell
line
see
materi
method
howev
experi
across
multipl
cell
line
deriv
vari
degre
murin
compon
produc
similar
result
fig
fig
c
observ
underscor
need
addit
model
flc
includ
new
cell
line
cell
line
describ
deriv
publish
flc
pdx
model
oikawa
et
al
therefor
deriv
addit
pdx
model
import
becom
avail
cell
line
deriv
inhibit
mapk
pathway
significantli
reduc
cell
viabil
effect
micromolar
rang
suggest
cell
exhibit
intrins
drug
resist
similar
report
patient
combin
treatment
mek
inhibitor
inhibitor
result
enhanc
potenc
compar
mek
inhibitor
alon
indic
inhibit
combin
addit
therapeut
might
viabl
treatment
strategi
flc
importantli
inhibitor
target
multipl
member
mapk
cascad
clinic
use
treatment
cancer
current
clinic
trial
metastat
pancreat
cancer
repurpos
therapeut
flc
patient
may
provid
effect
treatment
limit
option
current
avail
although
demonstr
inhibit
enhanc
potenc
mek
inhibitor
inhibit
flc
enhanc
hotspotassoci
gene
potenti
involv
drug
resist
tesc
vcan
may
provid
addit
therapeut
benefit
inde
knockdown
cell
express
enhanc
potenc
cobimetinib
demonstr
substanti
cytotox
activ
alon
sum
use
chroseq
map
transcript
enhanc
landscap
flc
genomescal
inform
provid
chroseq
allow
us
identifi
candid
master
transcript
regul
flc
novel
candid
flc
oncogen
demonstr
power
genom
approach
followup
function
studi
cell
express
newli
deriv
human
flc
cell
cultur
reveal
new
candid
therapeut
strategi
flc
inform
request
resourc
reagent
direct
fulfil
lead
contact
praveen
sethupathi
cornelledu
inform
consent
obtain
human
subject
sampl
collect
accord
institut
review
board
protocol
cornel
univers
andor
fibrolamellar
cancer
foundat
provid
fibrolamellar
cancer
foundat
importantli
sampl
come
patient
tabl
sampl
mice
obtain
previou
studi
dinh
et
al
remain
sampl
use
studi
briefli
femal
week
old
mice
subject
hydrodynam
tailvein
inject
steril
nacl
transposon
transposas
molar
ratio
transposon
plasmid
express
human
empti
control
ddc
diet
administ
tailvein
inject
express
egfp
previous
describ
dinh
et
al
cell
grown
dulbecco
modifi
eagl
media
dmem
contain
gl
glucos
thermo
fisher
scientif
supplement
fetal
bovin
serum
thermo
fisher
scientif
glutamax
thermo
fisher
scientif
mgl
sodium
pyruv
penicillinstreptomycin
thermo
fisher
scientif
kinasedead
mutant
clone
use
quikchang
ii
xl
sitedirect
mutagenesi
kit
agil
technolog
use
follow
primer
pcr
product
clone
pcrblunt
iitopo
vector
thermo
fisher
scientif
subclon
vector
addgen
plasmid
gift
tobia
meyer
lentiviru
product
cell
transfect
plasmid
along
addgen
plasmid
gift
didier
trono
addgen
plasmid
gift
didier
trono
produc
lentivir
particl
concentr
use
lentiviralx
concentr
takara
bio
usa
mountain
view
ca
per
manufactur
protocol
cell
transduc
vari
concentr
lentiviru
hour
select
puromycin
thermo
fisher
scientif
day
select
cell
treat
lowest
concentr
viru
use
passag
experi
obtain
major
cell
viral
integr
wt
cell
cell
express
fusion
previous
describ
dinh
et
al
cultur
supplement
fb
dexamethason
gentamicin
recombin
human
insulin
human
transferrin
ngml
sodium
selenit
flc
cell
previous
describ
dinh
et
al
line
grown
complet
f
medium
accord
previous
publish
protocol
liu
et
al
line
grown
similarli
line
three
minor
modif
first
f
media
condit
irradi
mous
embryon
fibroblast
day
prior
use
flc
cell
cultur
condit
f
media
without
irradi
fibroblast
second
rspondin
condit
media
ad
complet
f
media
volum
rspondin
condit
media
produc
cultur
cell
express
murin
gift
alexand
nikitin
lab
condit
media
dmem
supplement
glutamax
hepe
penicillinstreptomycin
day
supernat
collect
filter
filter
prior
use
third
rock
inhibitor
use
final
concentr
increas
origin
concentr
liu
et
al
detect
presenc
murin
cell
three
deriv
cell
line
rtqpcr
cell
line
cultur
chroseq
perform
previous
describ
chu
et
al
mahat
et
al
minor
modif
length
extens
chroseq
lechroseq
perform
ident
chroseq
except
indic
chromatin
isol
pulver
frozen
tissu
ml
nun
buffer
mm
hepe
mm
mm
edta
nacl
urea
mm
dtt
unitsml
superas
rnase
inhibitor
thermo
fisher
scientif
waltham
proteas
inhibitor
cocktail
roch
lechroseq
unitsml
rnase
cocktail
enzym
mix
thermo
fisher
scientif
substitut
superas
rnase
inhibitor
sampl
vortex
minut
addit
nun
buffer
ad
sampl
sampl
vortex
addit
minut
sampl
incub
eppendorf
thermomix
eppendorf
hamburg
germani
shake
rpm
minut
centrifug
x
g
minut
sampl
wash
ml
mm
trishcl
ph
supplement
unitsml
superas
rnase
inhibitor
unitsml
lechroseq
centrifug
x
g
minut
wash
step
repeat
twice
sampl
store
chromatin
storag
buffer
mm
trishcl
ph
glycerol
mm
magnesium
acet
mm
edta
mm
dtt
unitsml
superas
rnase
inhibitor
sampl
load
bioruptor
diagenod
denvil
nj
sonic
high
power
set
cycl
time
minut
consist
cycl
second
second
sonic
repeat
necessari
solubil
chromatin
sampl
store
follow
chromatin
isol
chromatin
mix
ul
runon
reaction
mix
copyright
holder
preprint
peerreview
http
inhibitor
sarkosyl
runon
reaction
perform
minut
rpm
stop
ad
trizol
ls
thermo
fisher
scientif
reaction
rna
sampl
precipit
resuspend
diethylpyrocarbon
depc
treat
water
heat
treat
second
digest
ice
naoh
minut
base
hydrolysi
naoh
exclud
lechroseq
protocol
nascent
rna
purifi
streptavidin
bead
new
england
biolab
neb
ipswich
previous
describ
chu
et
al
mahat
et
al
rna
purifi
bead
use
trizol
thermo
fisher
scientif
adaptor
ligat
perform
rna
ligas
neb
streptavidin
bead
bind
perform
follow
decap
rna
pyrophosphohydrolas
rpph
neb
end
rna
molecul
phosphoryl
polynucleotid
kinas
pnk
neb
adaptor
ligat
perform
rna
ligas
adaptor
contain
uniqu
molecular
identifi
umi
allow
bioinformat
detect
elimin
pcr
duplic
streptavidin
bead
bind
perform
follow
revers
transcript
use
superscript
iv
revers
transcriptas
thermo
fisher
scientif
cdna
amplifi
pcr
use
highfidel
dna
polymeras
neb
gener
le
chroseq
librari
librari
sequenc
singl
end
biotechnolog
research
center
cornel
univers
illumina
san
diego
ca
primer
sequenc
use
le
chroseq
librari
prepar
provid
tabl
small
rna
sequenc
perform
previous
describ
dinh
et
al
briefli
read
trim
use
cutadapt
map
genom
use
bowti
langmead
et
al
perfectli
align
read
repres
mirna
loci
imperfectli
map
read
deriv
isomir
realign
loci
use
shrimp
rumbl
et
al
align
read
quantifi
normal
use
read
per
million
map
mirna
data
avail
gene
express
omnibu
geo
access
number
read
qualiti
assess
use
fastqc
adapt
trim
end
read
use
cutadapt
martin
maximum
error
rate
minimum
bp
overlap
minimum
qualiti
score
read
contain
bp
umi
enabl
pcr
dedupl
collaps
umi
follow
umi
trim
use
prinseq
lite
schmieder
edward
process
read
minimum
length
bp
map
genom
modifi
addit
singl
copi
human
pol
ribosom
rna
complet
repeat
unit
genbank
bwa
li
durbin
use
bwabacktrack
algorithm
read
repres
singl
base
end
read
correspond
end
nascent
rna
data
convert
bigwig
format
use
bedtool
quinlan
hall
ucsc
bedgraphtobigwig
kent
et
al
visual
identif
tre
bigwig
file
ident
condit
merg
normal
total
signal
prior
visual
identifi
tre
across
sampl
bigwig
file
strand
sampl
flc
nml
merg
merg
dataset
use
call
tre
tre
sampl
identifi
dreg
danko
et
al
wang
et
al
use
peak
call
algorithm
read
count
quantifi
within
tre
locu
use
r
packag
bigwig
http
githubcomandrelmartinsbigwig
total
read
count
sens
antisens
strand
within
tre
across
sampl
import
love
et
al
analysi
tre
count
chroseq
reveal
follow
neg
binomi
distribut
similar
rnaseq
count
therefor
differenti
transcript
analysi
tre
perform
identifi
tre
significantli
differenti
transcrib
flc
nml
gene
definit
obtain
gencod
annot
avoid
count
read
paus
polymeras
peak
chroseq
signal
quantifi
sens
strand
bp
downstream
gene
start
annot
end
gene
gene
elimin
analysi
shorter
bp
protein
code
pseudogen
lincrna
antisens
mirna
gene
like
tre
count
gene
bodi
count
chroseq
follow
neg
binomi
distribut
therefor
differenti
transcript
analysi
gene
perform
use
tre
annot
perform
use
annotatepeakspl
function
homer
heinz
et
al
base
gencod
annot
transcript
factor
motif
enrich
analysi
perform
use
findmotifsgenomepl
function
homer
use
given
size
paramet
input
background
peak
run
flcspecif
tre
tre
identifi
flcspecif
background
nmlspecif
tre
tre
identifi
nmlspecif
flcspecif
tre
without
creb
motif
tre
identifi
flcspecif
flcspecif
promot
promot
identifi
flcspecif
flcspecif
enhanc
enhanc
identifi
flcspecif
cpg
island
annot
download
ucsc
tabl
browser
hierarch
cluster
perform
follow
normal
read
count
quantifi
tre
gene
bodi
describ
cluster
perform
pairwis
manner
use
correlationbas
distanc
metric
spearman
rho
use
ward
minimum
varianc
method
proxim
bp
tss
distal
tre
remain
tre
classifi
base
gencod
transcript
annot
princip
compon
analysi
perform
follow
varianc
stabil
transform
tre
function
enrich
analysi
perform
use
great
mclean
et
al
briefli
tre
convert
coordin
use
ucsc
liftov
tool
great
run
use
default
paramet
whole
genom
background
basal
plu
extens
associ
rule
gene
ontolog
analys
includ
kegg
ppi
hub
enrich
perform
use
enrichr
chen
et
al
window
enhanc
densiti
geneenhanc
correl
defin
use
gene
coordin
base
gencod
annot
flcspecif
enhanc
hotspot
identifi
use
method
analog
previous
describ
super
enhanc
et
al
whyte
et
al
first
distal
tre
tre
overlap
bp
tss
base
gencod
transcript
annot
stitch
togeth
use
stitch
distanc
kb
read
count
normal
within
distal
tre
quantifi
sampl
averag
tre
sum
stitch
enhanc
stitch
enhanc
rank
base
cumul
signal
threshold
super
enhanc
identif
determin
draw
line
tangent
signal
curv
stitch
enhanc
signal
point
identifi
tangent
line
classifi
flcspecif
enhanc
hotspot
coordin
known
super
enhanc
download
sedb
jiang
et
al
http
wwwlicpathwaynetsedb
encod
enhanc
coordin
download
search
candid
cisregulatori
element
encod
screen
http
screenwenglaborg
enhanc
coordin
download
http
nih
roadmap
epigenom
enhanc
coordin
download
honeybadg
http
data
download
coordin
sedb
encod
nih
roadmap
data
avail
download
coordin
convert
coordin
use
ucsc
liftov
tool
transcript
signal
quantifi
enhanc
gene
bodi
describ
gene
bodi
enhanc
count
normal
separ
use
pearson
correl
coeffici
normal
count
gene
enhanc
calcul
determin
statist
signific
calcul
correl
coeffici
construct
null
distribut
consist
correl
coeffici
gene
enhanc
differ
chromosom
geneenhanc
pair
within
kb
calcul
empir
pvalu
base
null
distribut
adjust
multipl
test
use
benjaminihochberg
fdr
procedur
benjamini
hochberg
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
heatmap
line
graph
visual
rna
polymeras
signal
gener
use
deeptool
et
al
genom
loci
snapshot
gener
use
gviz
hahn
ivanek
read
qualiti
assess
use
fastqc
read
map
genom
star
dobin
et
al
transcript
quantifi
salmon
patro
et
al
use
gencod
transcript
annot
normal
perform
use
tcga
rnaseq
data
download
use
tcgaassembl
wei
et
al
normal
count
tcga
rnaseq
data
lncrna
download
tanric
li
et
al
normal
count
cholangiocarcinoma
rnaseq
data
nakamura
et
al
download
european
genomephenom
archiv
access
number
gtex
releas
data
download
gtex
portal
gene
read
count
normal
rnaseq
data
primari
flc
use
princip
compon
analysi
perform
use
variabl
gene
follow
varianc
stabil
transform
read
qualiti
assess
use
fastqc
read
trim
map
quantifi
genom
use
mirquant
previous
describ
smrnaseq
analysi
pipelin
kank
et
al
briefli
read
trim
use
cutadapt
read
map
genom
use
bowti
langmead
et
al
perfectli
align
read
repres
mirna
loci
imperfectli
map
read
isomir
realign
loci
use
shrimp
rumbl
et
al
align
read
quantifi
normal
use
read
per
million
map
mirna
rpmmm
total
rna
isol
use
total
rna
purif
kit
norgen
biotek
per
manufactur
instruct
revers
transcript
perform
use
high
capac
rnatocdna
kit
thermo
fisher
scientif
gene
express
quantifi
taqman
gene
express
assay
thermo
fisher
scientif
touch
realtim
system
biorad
rna
express
level
normal
taqman
assay
use
provid
tabl
protein
lysat
prepar
use
ripa
buffer
sigma
st
loui
mo
supplement
proteas
inhibitor
cocktail
sigma
phosphatas
inhibitor
cocktail
sigma
mmoll
phenylmethylsulfonyl
fluorid
mmoll
dithiothreitol
protein
concentr
measur
use
pierc
bca
protein
assay
thermo
fisher
scientif
accord
manufactur
protocol
lysat
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
use
lysat
per
lane
denatur
condit
nupag
bistri
thermo
fisher
scientif
homemad
bistri
gel
transfer
pvdf
membran
use
standard
wet
transfer
protocol
membran
block
dri
nonfat
milk
tbst
probe
antibodi
enhanc
chemiluminesc
reagent
ge
healthcar
chicago
il
use
detect
cell
revers
transfect
use
lipofectamin
rnaimax
thermo
fisher
scientif
per
manufactur
instruct
briefli
transfect
mix
assembl
well
ad
pmol
appropri
sirna
rnaimax
plate
pmol
sirna
rnaimax
plate
accord
manufactur
protocol
optimem
ad
well
plate
incub
minut
room
temperatur
cell
plate
cell
plate
plate
top
transfect
mix
cell
incub
hour
prior
treatment
cell
seed
plate
seri
unit
dilut
cobimetinib
mm
stock
dmso
made
dmso
final
desir
concentr
stock
dilut
made
fresh
media
start
dilut
ad
appropri
well
use
multichannel
pipettor
result
dilut
final
dilut
final
volum
per
well
outer
plate
well
fill
media
nocellsnotreat
set
well
includ
background
cell
plate
grown
day
flc
cell
seed
plate
densiti
cellswel
volum
per
well
celltiterglo
promega
madison
wi
assay
follow
day
concentr
drug
dmso
prepar
media
remov
well
drug
vehicl
final
concentr
ad
well
cell
incub
hour
assess
cell
viabil
cell
viabil
assess
celltiterglo
crystal
violet
stain
celltiterglo
plate
remov
incub
place
room
temperatur
minut
equilibr
room
temperatur
celltiterglo
reagent
ad
cell
shaken
minut
plate
incub
min
room
temperatur
luminesc
measur
use
polarstar
omega
plate
reader
bmg
labtech
ortenberg
germani
em
filter
empti
gain
orbit
averag
diamet
cycl
synergi
micropl
reader
biotek
winooski
vt
area
scan
integr
time
second
crystal
violet
stain
cell
rins
pb
fix
paraformaldehyd
pb
minut
two
water
wash
perform
cell
stain
crystal
violet
methanol
minut
final
three
water
wash
perform
plate
allow
dri
room
temperatur
least
hour
imag
captur
custom
digit
photographi
setup
canon
mki
sigma
mm
len
quantifi
crystal
violet
stain
dye
dissolv
acet
acid
per
well
aliquot
remov
clear
plate
absorb
measur
use
polarstar
omega
plate
reader
bmg
labtech
signal
kept
linear
rang
dilut
acet
acid
necessari
rel
quantif
valu
rqv
calcul
normal
effect
drug
treatment
dmso
control
follow
celltiterglo
cell
viabil
experi
rqv
gener
replic
enter
effect
valu
appropri
drug
dosag
singl
combin
drug
treatment
compusyn
softwar
use
nonconst
ratio
design
paramet
individu
combin
index
valu
report
dose
combin
statist
analys
perform
use
r
statist
signific
primarili
determin
twosid
welch
ttest
mannwhitney
u
test
indic
figur
legend
altern
statist
test
use
note
text
figur
legend
statist
comparison
dose
respons
curv
perform
use
r
packag
drc
fit
loglogist
model
function
data
two
model
fit
data
one
one
without
sirna
compar
use
ftest
anova
function
determin
statist
signific
p
consid
statist
signific
unless
otherwis
note
p
p
p
selina
ruzi
assist
draw
figur
author
also
thank
john
hopper
dr
mark
furth
tom
stockwel
marna
davi
entir
fibrolamellar
cancer
foundat
support
patient
research
network
thank
ilya
finkelstein
biorxiv
templat
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
